M
Mark L. Ormiston
Researcher at University of Cambridge
Publications - 26
Citations - 1029
Mark L. Ormiston is an academic researcher from University of Cambridge. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 10, co-authored 14 publications receiving 826 citations. Previous affiliations of Mark L. Ormiston include Ottawa Hospital Research Institute & St. Michael's Hospital.
Papers
More filters
Journal ArticleDOI
Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.
Lu Long,Mark L. Ormiston,Xudong Yang,Mark Southwood,Stefan Gräf,Rajiv D. Machado,Matthias Mueller,Bernd Kinzel,Lai Ming Yung,Janine Mary Wilkinson,Stephen D Moore,Kylie M Drake,Micheala A. Aldred,Paul B. Yu,Paul D. Upton,Nicholas W. Morrell +15 more
TL;DR: Administration of BMP9 reversed established PAH in mice bearing a heterozygous knock-in allele of a human BMPR2 mutation, R899X, and demonstrated the promise of direct enhancement of endothelial BMP signaling as a new therapeutic strategy for PAH.
Journal ArticleDOI
Single-cell hydrogel encapsulation for enhanced survival of human marrow stromal cells.
TL;DR: Incorporation of immobilized adhesion molecules compensates, at least in part, for the missing cell-matrix cues, thereby attenuating the initial anoikis stimuli and providing protection from subsequent apoptosis in this single-cell encapsulation strategy.
Journal ArticleDOI
Impaired Natural Killer Cell Phenotype and Function in Idiopathic and Heritable Pulmonary Arterial Hypertension
Mark L. Ormiston,Chiwen Chang,Lu L. Long,Elaine Soon,Des C. Jones,Rajiv D. Machado,Carmen M. Treacy,Mark Toshner,Kate Campbell,Alex Riding,Mark Southwood,Joanna Pepke-Zaba,Andrew Exley,Richard C. Trembath,Francesco Colucci,Mark R. Wills,John Trowsdale,Nicholas W. Morrell +17 more
TL;DR: This work is the first to identify an impairment of NK cells in PAH and suggests a novel and substantive role for innate immunity in the pathobiology of this disease.
Journal ArticleDOI
Innate Immunity in the Therapeutic Actions of Endothelial Progenitor Cells in Pulmonary Hypertension
TL;DR: Data support a novel mode of action for human E-CMMs in the prevention of PAH, whereby they act through an immune-dependent mechanism, potentially involving the stimulation of NK cells.
Journal ArticleDOI
Proteomic Analysis Implicates Translationally Controlled Tumor Protein as a Novel Mediator of Occlusive Vascular Remodeling in Pulmonary Arterial Hypertension
Jessie R. Lavoie,Mark L. Ormiston,Carol Perez-Iratxeta,David W. Courtman,Baohua Jiang,Elisabet Ferrer,Paola Caruso,Mark Southwood,William S. Foster,Nicholas W. Morrell,Duncan J. Stewart +10 more
TL;DR: Proteomic screening identified translationally controlled tumor protein (TCTP) as a novel mediator of endothelial prosurvival and growth signaling in PAH, possibly contributing to occlusive pulmonary vascular remodeling triggered by EC apoptosis.